UNILIFE MEDICAL SOLUTION (157063 / UNIFF )
Seite 1 von 1 Neuester Beitrag: 12.02.10 14:18 | ||||
| Eröffnet am: | 22.08.09 17:38 | von: 0815ax | Anzahl Beiträge: | 14 |
| Neuester Beitrag: | 12.02.10 14:18 | von: 0815ax | Leser gesamt: | 7.054 |
| Forum: | Hot-Stocks | Leser heute: | 1 | |
| Bewertet mit: |  | |||
http://www.unilife.com/index.php
Financial Reports:
http://www.unilife.com/...gory§ionid=1&id=3&Itemid=77
Kurs-Übersicht:
DTL. (Direkthandel oder Börse Berlin) : http://www.ariva.de/quote/simple.m?secu=696194
OTCBB : http://www.ariva.de/quote/simple.m?secu=696194
Australien : http://finance.yahoo.com/q?s=UNI.AX&=
Finanznachrichten/NEWS:
http://www.unilife.com/...gory§ionid=1&id=1&Itemid=76
http://www.finanznachrichten.de/...tien/unilife-medical-solutions.asp
http://finance.yahoo.com/q?s=UNIFF.PK
**************************************************
Unilife Begins U.S. Production of Unitract Syringes
Written by Mike Havrilla
Wednesday, 12 August 2009 10:36
http://biomedreports.com/articles/most-popular/...tract-syringes.html
**************************************************
Analyst Reports
http://www.unilife.com/...tent&task=view&id=521&Itemid=78
Griffin Securities Initiation Report
19 August 2009
REPORT: http://www.unilife.com//...om_docman&task=doc_download&gid=56
&
Unilife : Griffin Initiates at Buy, US$3 Target
(UNI.AX) (UNIFF.PK)
Written by Mike Havrilla
Thursday, 20 August 2009 04:43
http://biomedreports.com/articles/most-popular/...buy-us3-target.html
The BioMedReports.com stock research section has been updated today with a research report for Unilife Medical Solutions (UNI.AX) (UNIFF.PK) written by Keith A. Markey, PhD, of Griffin Securities on 8/19/09 with a buy rating and $3 (U.S. Dollar) price target in addition to the most recent corporate presentation for the Company from 8/13/09.
Highlights from the report include the following:
1.) Unilife has a disruptive drug delivery technology with a sound strategy to enter the U.S. and European needle and syringe markets
2.) Unilife has a big pharma partner in Sanofi-Aventis (NYSE:SNY), which is investing $38 million into the Company through an industrialization agreement
3.) Starting next year, additional supply agreements in other therapeutic areas (outside of the SNY agreement) are anticipated
4.) Unilife expects to obtain a U.S. listing for its stock, since it has relocated its headquarters to Pennsylvania and also has a major manufacturing facility there
(Anmerkung: US$3 Target within next 12 month)
**************************************************
AGM Presentation by the CEO
http://www.unilife.com//...B_iframe=true&width=610&height=365
&
Unilife Medical Solutions Chairman's Letter to Shareholders
Tuesday August 18, 2009, 11:38 am EDT
http://finance.yahoo.com/news/...tions-iw-124254092.html?x=0&.v=1
**************************************************
Thread-Eröffnung (22.08.2009)
Kurs 21.08.09 Berlin : 0,407€
Kurs 21.08.08 OTCBB : 0,620$
**************************************************
...weitere Informationen zu finden hier: http://investorshub.advfn.com/boards/board.aspx?board_id=15924
in diesem Sinne 0815ax
uniff.png
http://www.unilife.com/...ntent&task=view&id=17&Itemid=34
- Sanofi-aventis
http://en.sanofi-aventis.com/
- West Pharmaceutical Services
http://west%20pharmaceutical%20services%20www.westpharma.com%20/
- Tessy Plastics
http://www.www.tessy.com/
- Shanghai Kindly Enterprise Development Group Limited (KDL)
http://www.kdlchina.com/
Price: $20
http://reports.finance.yahoo.com/w0?r=32383554:1
Price: --
http://www.unilife.com//...om_docman&task=doc_download&gid=56
Near-Term Milestones (Page 5/27 - Analyst Report)
REPORT: www.unilife.com//index.php
CORPORATE HISTORY
...
Oct./08 - Received FDA certification of the Unitract 1ml syringe via 510k application
Jan./09 - Consolidated operations in the United States
June/09 - Entered into industrialization agreement with sanofi-aventis for ready-to-fill syringes
NEAR-TERM-MILESTONES
Q3/09 - Locate a site for a new manufacturing plant in Pennsylvania
Q3/09 - Sign sourcing agreement for an automated manufacturing line (60 million units/year)
Q4/09 - Complete exclusivity list discussions with sanofi-aventis for certain drug classes
Q4/09 - List Unilife Medical Solutions stock an a major U.S. stock market
Q4/09 - Launch Unitract 1ml syringe in the United States and Europe
Q2/10 - Sign a ready-to-fill syringe supply agreement with a second drug company
H1/10 - Raise funds via an equity offering to help finance manufacturing equipment, inventory, and possibly a small acquisition
Q3/10 - Order equipment for first high-volume (150 million units/year) manufacturing line
H2/10 - Move in new manufacturing plant
Q4/10 - Complete work under the industrialization agreement for the ready-to-fill syringe
Q4/11 - Begin commercial shipments of ready-to-fill syringes to sanofi-aventis
04 August 2009
http://www.unilife.com/...tent&task=view&id=517&Itemid=77
...
Cash Reserves
During the quarter, receipts from customers of Unilife and its US subsidiary were $5.4 million. Net operating cash outflow for Unilife and its US subsidiary was $0.5 million. Unilife invested approximately $2.0 million in research and development and the purchase of plant and equipment. Unilife had cash reserves of $4.7 million as at 30 June 2009.
Details of Unilife’s cash flow are set out in the attached Appendix 4C.
http://www.unilife.com//...om_docman&task=doc_download&gid=52
Unilife Medical Solutions @ Rodman & Renshaw Annual Global Investment Conference
11th Annual Healthcare Conference
September 9-11,2009 New York Palace Hotel - New York, NY
www.rodmanandrenshaw.com/conferences
2009-09-10 // Henry Salon (5th Floor)
04:30 PM Unilife Medical Solutions Limited (ASX: UNI AU) 
Oct 21, 2009 10:04 ET
http://www.marketwire.com/press-release/...ution-ASX-UNI-1063118.html
...The Directors of Unilife Australia are pleased to confirm that the process for the NASDAQ listing has now commenced by way of filing a Form 10 registration statement for review by the US Securities and Exchange Commission (SEC), a precursor to applying for the NASDAQ listing. The Form 10 is available on the SEC's website at: http://www.sec.gov/cgi-bin/...01476170&owner=exclude&count=40 ...
Written by Mike Havrilla
Sunday, 13 December 2009 13:14
http://biomedreports.com/articles/most-popular/...rebound-likely.html
Unilife Medical Solutions Update on NASDAQ listing
NEWSROOM : http://www.proactivenewsroom.com/unilife/
January 15, 2010: 05:18 PM ET
http://money.cnn.com/news/newsfeeds/articles/marketwire/0577518.htm
The Company is now in the process of completing the final steps necessary for the listing of Unilife Corporation on NASDAQ. Subject to the Form 10 registration statement being declared effective by the SEC and Unilife Corporation's NASDAQ listing application being approved, Unilife Corporation expects its common stock to commence trading on NASDAQ on or around 10 February 2010.
The reserved NASDAQ ticker code for Unilife Corporation is "UNIS."
Comment from Unilife Chief Executive Officer, Alan Shortall
"Unilife has now received the final green light needed to complete our redomiciliation from Australia to the United States of America and move to finalising our listing on NASDAQ.
"During this transition period, which will result in Unilife Corporation becoming the trading entity for the Unilife Group, shareholders will need to be conscious of upcoming changes to our ticker codes. On 18 January 2010, our ASX code will change from 'UNI' to 'UNS' and Unilife Corporation CDIs will commence trading on ASX on a deferred settlement basis. From 2 February 2010, CDI trading should commence on a normal T+3 settlement basis.
"For those shareholders electing to retain their Unilife shares on the ASX as CDIs, there will be little apparent change apart from our Australian ticker code. Shareholders choosing to transfer their holdings to shares of Unilife Corporation common stock that will be tradeable on NASDAQ (subject to the application to list on NASDAQ being approved) will have their shares consolidated on a six to one basis. Following the NASDAQ listing, should shareholders wish to trade their shares of Unilife Corporation common stock, they may choose to either convert it back to CDIs or appoint a qualified broker with the capacity to trade in Unilife Corporation common stock on NASDAQ on their behalf."
Timetable to implementation
The Company would also like to take this opportunity to set out the timetable for completion of the redomiciliation:
Event Date
-------------------------------------------------- -----------------
Federal Court hearing for approval of the Schemes 14 January 2010
-------------------------------------------------- -----------------
Effective Date of the Schemes 15 January 2010
-------------------------------------------------- -----------------
Suspension of the Company's shares from trading on ASX 15 January 2010
-------------------------------------------------- -----------------
Unilife Corporation CDIs commence trading on ASX on a
deferred settlement basis 18 January 2010
-------------------------------------------------- -----------------
Record Date for the Schemes 22 January 2010
-------------------------------------------------- -----------------
Implementation Date for the Schemes 27 January 2010
-------------------------------------------------- -----------------
Despatch of holding statements and transmittal letters 1 February 2010
-------------------------------------------------- -----------------
CDIs commence trading on normal T+3 basis 2 February 2010
-------------------------------------------------- -----------------
Expected commencement date for listing on NASDAQ 10 February 2010
(subject to SEC
review of Form 10
and approval of
NASDAQ listing
application)
-------------------------------------------------- -----------------
All dates and times are indicative only and are subject to change.
All dates and times are Australian Eastern Daylight Time
About Unilife
Unilife Medical Solutions Ltd. is an ISO 13485 certified company that designs, develops and supplies innovative safety medical devices. Listed on the Australian Securities Exchange (ASX: UNI) since 2002, Unilife has FDA-registered manufacturing facilities in the US State of Pennsylvania and a proprietary portfolio of clinical and prefilled safety syringes designed for use within healthcare and pharmaceutical markets.
Shareholder / Analyst Enquiries:
Australia
Jeff Carter
Phone: + 61 2 8346 6500
United States
Stuart Fine
Phone: + 1 908 469 1788
http://www.finanznachrichten.de/...declares-form-10-effective-008.htm
Unilife Corporation to Commence Trading on the NASDAQ Global Market / SEC DECLARES FORM 10 EFFECTIVE
LEWISBERRY, Pa., Feb. 12 /PRNewswire-FirstCall/ -- Unilife Corporation (Company) today announced that the US Securities and Exchange Commission (SEC) declared the Company's Form 10 registration statement effective, clearing the path for Unilife Corporation's listing on the NASDAQ.
The Company expects trading of Unilife Corporation common stock to commence on NASDAQ on or around February 16, 2010 under the ticker "UNIS".
Alan Shortall, CEO of Unilife, stated, "I would like to thank the Unilife team for the completion of this significant corporate milestone. In particular, I wish to note the important contribution made by the Unilife Finance department, and our Australian and US legal representatives, DLA Phillips Fox and DLA Piper who worked tirelessly to achieve this approval within our projected timeframe.
"Despite severe weather conditions in the eastern portion of the US that caused a shutdown of all Federal Government offices in Washington, DC, and restricted operations in both Pennsylvania and New York City, our team has been able to work co-operatively to complete the work necessary to achieve this result. I must compliment the Unilife team and our advisors for an outstanding effort."
The Company also wishes to advise that by the time trading of Unilife common stock commences on NASDAQ, it will have published on its website (http://www.unilife.com/) a list of Frequently Asked Questions (FAQs) to support shareholders wishing to trade on either the ASX or NASDAQ. The Company has also now opened an Investor Hotline to assist with shareholder enquiries during this period. The enquiry line numbers are 1800 632 680 (Australia toll free), +1 866 496 5819 (US toll free) and or +61 2 8256 3394 (International).
About Unilife Corporation
Unilife Corporation are a US based medical device company focused on the design, development, manufacture and supply of a proprietary range of retractable syringes. Primary target customers for Unilife products include pharmaceutical manufacturers, suppliers of medical equipment to healthcare facilities and patients who self-administer prescription medication. These patent-protected syringes incorporate automatic and fully-integrated safety features which are designed to protect those at risk of needlestick injuries and unsafe injection practices. Unilife is ISO 13485 certified and has FDA-registered medical device manufacturing facilities in Pennsylvania.
Unilife's main product is the Unifill(TM) ready-to-fill syringe, which is designed to be supplied to pharmaceutical manufacturers in a form that is ready for filling with injectable drugs and vaccines. The Company has a strategic partnership with sanofi-aventis, who has the exclusive right to negotiate for the purchase of the Unifill(TM) syringe and is funding an industrialization program for the product. In addition, Unilife has retained the right to negotiate with other pharmaceutical companies seeking to utilize the Unifill syringe with drugs and vaccines marketed in therapeutic areas outside of those secured exclusively by sanofi-aventis.
This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our registration statement on Form 10 and those described from time to time in our future reports which we will file with the Securities and Exchange Commission.
Investor Contacts (US): Todd Fromer / Garth Russell KCSA Strategic Communications + 1 212-682-6300
Unilife Corporation
CONTACT: Todd Fromer or Garth Russell, both of KCSA Strategic
Communications, +1-212-682-6300
Web Site: http://www.unilife.com/